228 related articles for article (PubMed ID: 32513774)
21. Deletion of inositol polyphosphate 4-phosphatase type-II B affects spermatogenesis in mice.
Ceyhan Y; Zhang M; Guo J; Sandoval CG; Vacher J; Kaftanovskaya EM; Agoulnik AI; Agoulnik IU
PLoS One; 2020; 15(5):e0233163. PubMed ID: 32413098
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic inactivation of inositol polyphosphate 4-phosphatase B (INPP4B), a regulator of PI3K/AKT signaling pathway in EBV-associated nasopharyngeal carcinoma.
Yuen JW; Chung GT; Lun SW; Cheung CC; To KF; Lo KW
PLoS One; 2014; 9(8):e105163. PubMed ID: 25126743
[TBL] [Abstract][Full Text] [Related]
23. PTEN Regulates PI(3,4)P
Malek M; Kielkowska A; Chessa T; Anderson KE; Barneda D; Pir P; Nakanishi H; Eguchi S; Koizumi A; Sasaki J; Juvin V; Kiselev VY; Niewczas I; Gray A; Valayer A; Spensberger D; Imbert M; Felisbino S; Habuchi T; Beinke S; Cosulich S; Le Novère N; Sasaki T; Clark J; Hawkins PT; Stephens LR
Mol Cell; 2017 Nov; 68(3):566-580.e10. PubMed ID: 29056325
[TBL] [Abstract][Full Text] [Related]
24. INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.
Jin H; Yang L; Wang L; Yang Z; Zhan Q; Tao Y; Zou Q; Tang Y; Xian J; Zhang S; Jing Y; Zhang L
J Exp Clin Cancer Res; 2018 Jan; 37(1):8. PubMed ID: 29343273
[TBL] [Abstract][Full Text] [Related]
25. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
Montero JC; Esparís-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocaña A; Pandiella A
Oncogene; 2014 Jan; 33(2):148-56. PubMed ID: 23246963
[TBL] [Abstract][Full Text] [Related]
26. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.
Gewinner C; Wang ZC; Richardson A; Teruya-Feldstein J; Etemadmoghadam D; Bowtell D; Barretina J; Lin WM; Rameh L; Salmena L; Pandolfi PP; Cantley LC
Cancer Cell; 2009 Aug; 16(2):115-25. PubMed ID: 19647222
[TBL] [Abstract][Full Text] [Related]
27. INPP4B is an oncogenic regulator in human colon cancer.
Guo ST; Chi MN; Yang RH; Guo XY; Zan LK; Wang CY; Xi YF; Jin L; Croft A; Tseng HY; Yan XG; Farrelly M; Wang FH; Lai F; Wang JF; Li YP; Ackland S; Scott R; Agoulnik IU; Hondermarck H; Thorne RF; Liu T; Zhang XD; Jiang CC
Oncogene; 2016 Jun; 35(23):3049-61. PubMed ID: 26411369
[TBL] [Abstract][Full Text] [Related]
28. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
[TBL] [Abstract][Full Text] [Related]
29. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
Linklater ES; Tovar EA; Essenburg CJ; Turner L; Madaj Z; Winn ME; Melnik MK; Korkaya H; Maroun CR; Christensen JG; Steensma MR; Boerner JL; Graveel CR
Oncotarget; 2016 Oct; 7(43):69903-69915. PubMed ID: 27655711
[TBL] [Abstract][Full Text] [Related]
30. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.
Hodgson MC; Shao LJ; Frolov A; Li R; Peterson LE; Ayala G; Ittmann MM; Weigel NL; Agoulnik IU
Cancer Res; 2011 Jan; 71(2):572-82. PubMed ID: 21224358
[TBL] [Abstract][Full Text] [Related]
31. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress.
Jabbarzadeh Kaboli P; Luo S; Chen Y; Jomhori M; Imani S; Xiang S; Wu Z; Li M; Shen J; Zhao Y; Wu X; Hin Cho C; Xiao Z
Gene; 2022 Mar; 816():146171. PubMed ID: 35026293
[TBL] [Abstract][Full Text] [Related]
32. Metalloprotease-dependent activation of EGFR modulates CD44
Wise R; Zolkiewska A
Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
[TBL] [Abstract][Full Text] [Related]
33. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
Duncan JS; Whittle MC; Nakamura K; Abell AN; Midland AA; Zawistowski JS; Johnson NL; Granger DA; Jordan NV; Darr DB; Usary J; Kuan PF; Smalley DM; Major B; He X; Hoadley KA; Zhou B; Sharpless NE; Perou CM; Kim WY; Gomez SM; Chen X; Jin J; Frye SV; Earp HS; Graves LM; Johnson GL
Cell; 2012 Apr; 149(2):307-21. PubMed ID: 22500798
[TBL] [Abstract][Full Text] [Related]
34. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
35. INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway.
Chen Y; Sun Z; Qi M; Wang X; Zhang W; Chen C; Liu J; Zhao W
J Cell Mol Med; 2018 May; 22(5):2935-2943. PubMed ID: 29516642
[TBL] [Abstract][Full Text] [Related]
36. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
37. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
[TBL] [Abstract][Full Text] [Related]
38. Regulation of B-1 cell numbers and B cell-mediated antibody production by Inpp4b.
Xu M; Ren J; Jia W; Wang S; Liu Y; Chen X; Shi J; Wang H
Scand J Immunol; 2023 Oct; 98(4):e13309. PubMed ID: 37389566
[TBL] [Abstract][Full Text] [Related]
39. SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.
Gasser JA; Inuzuka H; Lau AW; Wei W; Beroukhim R; Toker A
Mol Cell; 2014 Nov; 56(4):595-607. PubMed ID: 25458846
[TBL] [Abstract][Full Text] [Related]
40. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
